Home Uncategorized Page 9

Uncategorized

Latest

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase...

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Henrik Dahl’s Review of Pickard’s ‘The Rose of Paracelsus: On Secrets...

Markets for Feb 26: $AION +8.33%, $CYBN -19.19%, $FTRP -13.09%

Psychedelic Spotlight: Entheon Biomedical

Markets for Feb 24: $AION -18.75%, $TRIP +12.64%, $MCUR +11.53%

A New Path To Wealth: Navigating The Psychedelic Investment Landscape

1...8910...13 Page 9 of 13

Taking the Leap: Skydiving, Psychedelics, and Unlocking Personal Potential

Psychedelic Alpha’s Top 11 Stories from 2024

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Uncategorized

Hello world!

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase...

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

July 2020 Newsletter

June 2020 Newsletter

CLINICAL RESEARCH ASSOCIATE